Why this Symposium?
Antimicrobial resistance (AMR) is considered the biggest global threat of Health and Food Safety (Source: WHO[i]). AMR develops when bacteria, fungi, or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, caesarian sections, chemotherapy and stem cell therapy may become impossible. It is estimated that AMR causes at least 700,000 casualties per year with the low- and middle income countries (LMIC) bearing the harshest burdens. More recent recalculations indicate substantially higher numbers.
According to the ‘Review on Antimicrobial Resistance’ by Jim O’Neill we may face some 10,000,000 casualties per year in 2050 with cumulative GDP loss of $ 100 trillion[ii].
“Planet earth faces the very real threat of having to survive in a ‘post-antibiotic’ era in which there are few, if any, antibiotics which effectively and affordably cure infections”[iii].
The global curbing of AMR demands for urgent action. Both at an international as well as at a national level action plans have been set up to fight AMR. These plans have five ‘strategies’ in common:
- Better prevention of infectious diseases
- Further implementing antibiotics stewardship
- Developing improved microbiological diagnostics
- Developing novel (classes of) antibiotics and antimicrobials
- Developing alternative antimicrobial strategies (like phage therapy).
Emerging antimicrobials, alternative antimicrobial strategies and diagnostics play an increasingly important role in curbing AMR.
Emerging Antimicrobials and Diagnostics deserve a podium
Academic researchers, Start-up’s, SME’s and multinational companies within and outside Europe are developing novel powerful antibiotics and other antimicrobials, vaccines and microbial diagnostics. Technologies we desperately need in the global fight against Antimicrobial resistance. Meanwhile many of these emerging technologies are not, or not sufficiently, in the spotlights of Big Pharma and Diagnostic companies and end users such as Healthcare Institutions, GP’s/vets, Diagnostic Laboratories, NGO’s and Authorities.
The Symposium provides an excellent podium
‘Emerging Antimicrobials and Diagnostics in AMR 2019’ will provide an excellent podium for emerging Antimicrobials and Diagnostics. In addition, the event will offer key note presentations on AMR, technology updates, matchmaking sessions as well as a plenary forum discussion, info/expo market and ample networking opportunities.